We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

108 hedge funds and large institutions have $882M invested in Theravance Biopharma in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 41 increasing their positions, 26 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

73% more call options, than puts

Call options by funds: $1.45M | Put options by funds: $838K

58% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 26

2.32% more ownership

Funds ownership: 82.09% → 84.41% (+2.3%)

5% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 19

1% more funds holding

Funds holding: 107 → 108 (+1)

19% less capital invested

Capital invested by funds: $1.09B → $882M (-$210M)

Holders
108
Holders Change
+1
Holders Change %
+0.93%
% of All Funds
1.88%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
20
Increased
41
Reduced
26
Closed
19
Calls
$1.45M
Puts
$838K
Net Calls
+$613K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
MS
Maven Securities
Jersey
+$25.2M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$23.7M
3
BG
Baupost Group
Massachusetts
+$22.1M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$19.9M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$14.3M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$31.1M
2
CAM
Cormorant Asset Management
Massachusetts
-$4.69M
3
UBS Group
UBS Group
Switzerland
-$4.11M
4
Deutsche Bank
Deutsche Bank
Germany
-$3.14M
5
BlackRock
BlackRock
New York
-$2.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$4.18M +$125K +6,639 +2%
Hudson Bay Capital Management
27
Hudson Bay Capital Management
Connecticut
$3.49M +$1.32M +70,437 +41%
ACM
28
Altium Capital Management
New York
$3.19M +$4.13M +220,000 New
PAMU
29
Pictet Asset Management (UK)
United Kingdom
$3.06M +$664K +35,351 +20%
MIM
30
Monashee Investment Management
Massachusetts
$2.9M +$3.76M +200,000 New
Wells Fargo
31
Wells Fargo
California
$2.75M +$122K +6,480 +4%
N
32
Nuveen
North Carolina
$2.73M -$79.2K -4,215 -2%
PAM
33
Panagora Asset Management
Massachusetts
$2.6M -$149K -7,915 -4%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$2.55M -$506K -26,950 -13%
Millennium Management
35
Millennium Management
New York
$2.19M +$595K +31,682 +27%
Swiss National Bank
36
Swiss National Bank
Switzerland
$1.73M +$314K +16,700 +16%
FCM
37
Farallon Capital Management
California
$1.39M +$1.8M +96,000 New
ECM
38
ExodusPoint Capital Management
New York
$1.32M +$1.71M +90,864 New
Russell Investments Group
39
Russell Investments Group
United Kingdom
$1.19M -$96.3K -5,128 -6%
MOACM
40
Mutual of America Capital Management
New York
$1.15M -$64K -3,410 -4%
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$1.07M +$58.5K +3,116 +4%
Bank of America
42
Bank of America
North Carolina
$1.04M -$575K -30,637 -30%
AllianceBernstein
43
AllianceBernstein
Tennessee
$1.03M – – –
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
$953K – – –
HWAM
45
Hennion & Walsh Asset Management
New Jersey
$947K -$700K -37,302 -36%
UBS AM
46
UBS AM
Illinois
$928K +$58.7K +3,127 +5%
CS
47
Credit Suisse
Switzerland
$910K +$261K +13,888 +28%
CCM
48
CAAS Capital Management
New York
$892K +$1.15M +61,450 New
RA
49
Royce & Associates
New York
$857K – – –
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$848K -$58.3K -3,104 -5%
1
2
3 4 5

TBPH Hedge Fund Activity: Q2 2021 in Review

108 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2021, worth a combined $882M — down 19% from $1.09B a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new TBPH positions and 19 closed out — a net gain of 1 holder — while 41 added to existing stakes and 26 trimmed.

The largest buyer was Maven Securities, opening a new position worth an estimated $25.2M. The largest seller was OrbiMed, cutting an estimated $31.1M.

  • 108 institutional investors held Theravance Biopharma (TBPH) as of Q2 2021, up from 107 in Q1 2021.
  • Funds reported $882M of Theravance Biopharma stock for Q2 2021, down 19% quarter-over-quarter.
  • 20 funds opened new Theravance Biopharma positions in Q2 2021 and 19 closed out, a net change of +1 holder.
  • The largest Theravance Biopharma buyer in Q2 2021 was Maven Securities, an estimated $25.2M added.
  • The largest Theravance Biopharma seller in Q2 2021 was OrbiMed, an estimated $31.1M sold.

Based on aggregated 13F filings for Q2 2021.